氨酸及其膜受体CD44和RHAMM在与肥胖相关的脏病理学中的新型作用
Bingxue Qi1,2, Vishal Musale1, Xiong Weng1
1Division of Diabetes, Endocrinology and Reproductive Biology, School of Medicine, University of Dundee, Dundee DD1 9SY, UK.
Biomolecules
|November 27, 2025
概括
与肥胖相关的病理包括氨酸 (HA) 和其受体CD44/RHAMM,有助于损伤. 向HA-CD44/RHAMM通路为预防慢性病提供了一个新的治疗策略.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 分子生物学分子生物学
- 病理学 病理学 病理学
背景情况:
- 与肥胖相关的病理 (ORKP) 是一个重要的全球健康问题,加剧糖尿病病并增加癌风险.
- 目前的ORKP治疗受到其潜在疾病机制的有限理解的阻碍.
- 氨酸 (HA) 和它的受体CD44和RHAMM与各种纤维状况有关.
研究的目的:
- 研究氨酸 (HA) 和其膜受体CD44和RHAMM在与肥胖相关的病理 (ORKP) 中的作用.
- 阐明将HA-CD44/RHAMM信号与肥胖症中的损伤联系起来的分子通路.
- 评估ORKP中准HA-CD44/RHAMM轴的治疗潜力.
主要方法:
- 利用体内模型来评估肥胖对功能和病理学的影响.
- 采用药理和基因废除策略来抑制HA,CD44或RHAMM.
- 使用人类细胞进行了体外研究,以探索胰岛素抵抗和细胞外矩阵 (ECM) 改造之间的联系.
- 分析了人类脏活检样本,以将CD44/RHAMM表达与脏功能障碍标志物的相关性.
主要成果:
- 肥胖症显著增加脏HA沉积和CD44/RHAMM表达,激活有害的信号通路 (TGF-β1/Smad2/3,P38/JNK MAPK,ROCK/ERK).
- 这些途径导致质细胞病变,管道损伤,炎症,白色素尿和血清肌氨酸升高.
- 对HA,CD44或RHAMM的药理或遗传抑制在体内有效地逆转了肥胖引起的病理.
- 人类脏活检显示慢性病和糖尿病病中CD44和RHAMM的升高,与功能障碍标志物相关.
结论:
- 氨 (HA),CD44和RHAMM在与肥胖相关的病理学中起着关键的,有害的作用.
- 针对HA-CD44/RHAMM轴为ORKP提供了一个有前途的治疗策略.
- 这种方法有可能预防慢性病的进展.
关键词:
在CD4444中,我们可以看到CD44.拉姆 (RHAMM) 是一个词.这是一种色.胰岛素耐药性是一种胰岛素耐药性.脏 脏 脏是什么?鼠标 鼠标 鼠标 鼠标肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖更多相关视频
相关概念视频
External Anatomy of the Kidney
3.3K
The kidneys are a pair of bean-shaped organs in the human body that play a critical role in maintaining overall health. They filter out waste products from the blood, regulate blood pressure, maintain electrolyte balance, and stimulate the production of red blood cells.
The kidneys are located in the retroperitoneal space on either side of the vertebral column, protected posteriorly by the 11th and 12th ribs. The right kidney sits slightly lower than the left owing to the presence of the liver...
The kidneys are located in the retroperitoneal space on either side of the vertebral column, protected posteriorly by the 11th and 12th ribs. The right kidney sits slightly lower than the left owing to the presence of the liver...
3.3K
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Nephrotic Syndrome I : Introduction
476
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
476
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
162
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
162
Hypertension II: Pathophysiology
763
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
763
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
228
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
228


